X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5714) 5714
Publication (403) 403
Book Review (167) 167
Book Chapter (44) 44
Newsletter (42) 42
Magazine Article (14) 14
Conference Proceeding (13) 13
Newspaper Article (5) 5
Web Resource (5) 5
Trade Publication Article (4) 4
Book / eBook (2) 2
Transcript (2) 2
Dissertation (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
clopidogrel (5076) 5076
humans (4742) 4742
index medicus (3565) 3565
platelet aggregation inhibitors - therapeutic use (3237) 3237
ticlopidine - analogs & derivatives (2681) 2681
male (2551) 2551
female (2368) 2368
aspirin (2360) 2360
ticlopidine - therapeutic use (2260) 2260
middle aged (2009) 2009
aged (1983) 1983
cardiac & cardiovascular systems (1751) 1751
aspirin - therapeutic use (1429) 1429
treatment outcome (1411) 1411
percutaneous coronary intervention (1295) 1295
risk factors (1120) 1120
acute coronary syndromes (1037) 1037
platelet aggregation inhibitors - adverse effects (1023) 1023
antiplatelet therapy (1014) 1014
pharmacology & pharmacy (999) 999
drug therapy, combination (961) 961
peripheral vascular disease (910) 910
myocardial-infarction (817) 817
risk (798) 798
stroke (759) 759
prasugrel (743) 743
drug therapy (714) 714
hematology (714) 714
thrombosis (714) 714
abridged index medicus (697) 697
stents (695) 695
ticlopidine - adverse effects (685) 685
platelet aggregation - drug effects (657) 657
platelet aggregation inhibitors - administration & dosage (646) 646
therapy (645) 645
acute coronary syndrome - drug therapy (636) 636
ticagrelor (636) 636
care and treatment (633) 633
coronary heart disease (613) 613
prevention (607) 607
medicine, general & internal (593) 593
blood platelets (589) 589
cardiology (584) 584
heart attacks (583) 583
time factors (573) 573
mortality (565) 565
platelet aggregation inhibitors - pharmacology (561) 561
acute coronary syndrome (557) 557
intervention (543) 543
prospective studies (537) 537
blood platelets - drug effects (534) 534
adult (530) 530
aged, 80 and over (527) 527
trial (522) 522
ticlopidine - administration & dosage (506) 506
cardiovascular disease (495) 495
aggregation (485) 485
cardiovascular diseases (484) 484
hemorrhage - chemically induced (482) 482
cardiac patients (481) 481
acute myocardial-infarction (462) 462
research (462) 462
retrospective studies (447) 447
dosage and administration (446) 446
analysis (436) 436
cardiovascular (436) 436
anticoagulants - therapeutic use (433) 433
purinergic p2y receptor antagonists - therapeutic use (419) 419
myocardial infarction (412) 412
aspirin - adverse effects (411) 411
outcomes (406) 406
platelet function tests (395) 395
platelets (394) 394
patients (393) 393
risk assessment (393) 393
adenosine - analogs & derivatives (381) 381
medicine & public health (379) 379
ticlopidine - pharmacology (379) 379
stroke - prevention & control (377) 377
inhibition (374) 374
platelet reactivity (373) 373
myocardial infarction - drug therapy (368) 368
anticoagulants (367) 367
stent thrombosis (365) 365
angioplasty (364) 364
aspirin - administration & dosage (362) 362
follow-up studies (356) 356
surgery (354) 354
artery-disease (353) 353
health aspects (353) 353
secondary prevention (347) 347
randomized controlled trials as topic (345) 345
drug resistance (341) 341
clinical trials (335) 335
st-segment elevation (335) 335
ticlopidine (330) 330
warfarin (328) 328
events (327) 327
fibrinolytic agents - therapeutic use (327) 327
management (326) 326
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5658) 5658
German (43) 43
French (32) 32
Russian (31) 31
Spanish (29) 29
Polish (8) 8
Japanese (6) 6
Turkish (5) 5
Chinese (3) 3
Portuguese (3) 3
Dutch (2) 2
Italian (2) 2
Korean (2) 2
Hungarian (1) 1
Norwegian (1) 1
Romanian (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 10/2017, Volume 377, Issue 16, pp. 1513 - 1524
In this trial, dabigatran plus a P2Y 12 inhibitor was compared with warfarin plus a P2Y 12 inhibitor and aspirin after PCI in patients with atrial... 
MEDICINE, GENERAL & INTERNAL | PERCUTANEOUS CORONARY INTERVENTION | HEART-DISEASE | MYOCARDIAL-INFARCTION | ORAL ANTICOAGULATION | 2011 ACCF/AHA/SCAI GUIDELINE | AMERICAN-COLLEGE | ASSOCIATION TASK-FORCE | TRIPLE THERAPY | ANTIPLATELET THERAPY | CONSENSUS DOCUMENT | Dabigatran - adverse effects | Ticlopidine - therapeutic use | Humans | Middle Aged | Warfarin - adverse effects | Male | Risk | Dabigatran - therapeutic use | Incidence | Warfarin - therapeutic use | Purinergic P2Y Receptor Antagonists - adverse effects | Drug Therapy, Combination - adverse effects | Adenosine - adverse effects | Adenosine - therapeutic use | Female | Aspirin - therapeutic use | Platelet Aggregation Inhibitors - therapeutic use | Ticagrelor | Purinergic P2Y Receptor Antagonists - therapeutic use | Hemorrhage - epidemiology | Atrial Fibrillation - drug therapy | Atrial Fibrillation - therapy | Anticoagulants - therapeutic use | Anticoagulants - adverse effects | Ticlopidine - analogs & derivatives | Adenosine - analogs & derivatives | Clopidogrel | Aged | Hemorrhage - chemically induced | Percutaneous Coronary Intervention | Warfarin | Atrial fibrillation | Dosage and administration | Research | Thromboembolism | Hemorrhage | Health aspects | Myocardial infarction | Cerebral infarction | Cardiac arrhythmia | Anticoagulants | Aspirin | Stroke | Embolisms | Preventive medicine | Thrombosis | Bleeding | Embolism | Fibrillation | Cardiology | Drug therapy | Drug dosages | Geriatrics | Kardiologi | Clinical Medicine | Cardiac and Cardiovascular Systems | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2008, Volume 359, Issue 12, pp. 1238 - 1251
In this large clinical trial, aspirin plus extended-release dipyridamole was found to have an efficacy similar to that of clopidogrel in the prevention of... 
ISSUES | MEDICINE, GENERAL & INTERNAL | PLACEBO | DESIGN | TICLOPIDINE | WARFARIN | TRANSIENT ISCHEMIC ATTACK | DOUBLE-BLIND | PREVENTION | REGIMENS | NON-INFERIORITY TRIALS | Myocardial Infarction - epidemiology | Benzoates - therapeutic use | Ticlopidine - therapeutic use | Humans | Middle Aged | Male | Risk | Secondary Prevention | Aspirin - administration & dosage | Vascular Diseases - mortality | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Dipyridamole - adverse effects | Female | Stroke - epidemiology | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Dipyridamole - therapeutic use | Benzimidazoles - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Brain Ischemia - epidemiology | Stroke - prevention & control | Double-Blind Method | Kaplan-Meier Estimate | Proportional Hazards Models | Brain Ischemia - prevention & control | Factor Analysis, Statistical | Stroke - drug therapy | Ticlopidine - analogs & derivatives | Aged | Hemorrhage - chemically induced | Delayed-Action Preparations | Stroke (Disease) | Aspirin | Usage | Care and treatment | Dipyridamole | Clopidogrel | Health aspects | Stroke | Index Medicus | Abridged Index Medicus | Recurrence | Brain Ischemia | Benzimidazoles | Follow-Up Studies | Neurons and Cognition | Cognition | Hemorrhage | Drug Delivery Systems | Life Sciences | Angiotensin II Type 1 Receptor Blockers | Angiotensin-Converting Enzyme Inhibitors | Vascular Diseases | Mental Status Schedule | Retrospective Studies | Severity of Illness Index | Disability Evaluation | Benzoates | Drug Administration Schedule | International Cooperation | Ticlopidine | Myocardial Infarction | Platelet Aggregation Inhibitors | Santé publique et épidémiologie | Original | Dipyridamole/adverse effects/therapeutic use | Angiotensin-Converting Enzyme Inhibitors/therapeutic use | Recurrence/prevention & control | Benzoates/therapeutic use | Brain Ischemia/epidemiology/prevention & control | MEDICIN OCH HÄLSOVETENSKAP | Platelet Aggregation Inhibitors/administration & dosage/adverse | Combination | MEDICAL AND HEALTH SCIENCES | Aspirin/administration & dosage/adverse effects | Myocardial Infarction/epidemiology | Factor Analysis | Benzimidazoles/therapeutic use | Drug Therapy | Ticlopidine/adverse effects/analogs & derivatives/therapeutic use | effects/therapeutic use | Vascular Diseases/mortality | Hemorrhage/chemically induced | Stroke/drug therapy/epidemiology/prevention & control | Statistical | Kaplan-Meiers Estimate
Journal Article
Circulation, ISSN 0009-7322, 02/2013, Volume 127, Issue 5, pp. 634 - 640
Journal Article
Circulation, ISSN 0009-7322, 04/2011, Volume 123, Issue 16, pp. 1745 - 1756
Background-Concerns persist regarding the risk of stent thrombosis in the setting of primary percutaneous coronary intervention for ST-segment elevation... 
stents | thrombosis | myocardial infarction | CARDIAC & CARDIOVASCULAR SYSTEMS | RANDOMIZED-TRIALS | BARE-METAL STENTS | ROUTINE CLINICAL-PRACTICE | UNCOATED STENTS | CLOPIDOGREL | IMPLANTATION | LARGE 2-INSTITUTIONAL COHORT | PLATELET INHIBITION | PERIPHERAL VASCULAR DISEASE | ST-SEGMENT ELEVATION | HEMATOLOGY | DRUG-ELUTING STENTS | Recombinant Proteins - therapeutic use | Predictive Value of Tests | Myocardial Infarction - epidemiology | Coronary Thrombosis - epidemiology | Ticlopidine - therapeutic use | Hirudins | Humans | Metals | Middle Aged | Heparin - therapeutic use | Male | Angioplasty, Balloon, Coronary - statistics & numerical data | Drug-Eluting Stents - adverse effects | Angioplasty, Balloon, Coronary - adverse effects | Myocardial Infarction - therapy | Coronary Thrombosis - prevention & control | Drug-Eluting Stents - statistics & numerical data | Female | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Antithrombins - therapeutic use | Risk Factors | Anticoagulants - therapeutic use | Coronary Restenosis - prevention & control | Treatment Outcome | Paclitaxel - therapeutic use | Ticlopidine - analogs & derivatives | Tubulin Modulators - therapeutic use | Coronary Restenosis - epidemiology | Aged | Peptide Fragments - therapeutic use | Complications and side effects | Care and treatment | Angioplasty | Research | Thrombosis | Heart attack | Stent (Surgery) | Blood clot | Risk factors
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2012, Volume 367, Issue 14, pp. 1297 - 1309
Journal Article